Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Aparna R ParikhEmily E Van SeventerGiulia SiravegnaAnna V HartwigAriel JaimovichYupeng HeKatie N KanterMadeleine G FishKathryn D FosbennerBenchun MiaoSusannah PhillipsJohn H CarmichaelNihaarika SharmaJoy X JarnaginIslam BaievYojan S ShahIsobel J FetterHeather A ShahzadeJill N AllenLawrence S BlaszkowskyJeffrey W ClarkJon S DuboisJoseph W FransesBruce J GiantonioLipika GoyalSamuel J KlempnerRyan D NippEric J RoelandDavid P RyanColin D WeekesJennifer Y WoTheodore S HongLiliana BordeianouCristina R FerroneMotaz QadanHiroko KunitakeDavid BergerRocco RicciardiJames C CusackVictoria M RaymondAmirAli TalasazGenevieve Marie BolandRyan B CorcoranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection.See related commentary by Bent and Kopetz, p. 5449.